COMMUNIQUÉS West-GlobeNewswire

Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission
01/09/2026
Multi-site clinical study delivers strong performance data for Intelligent Fingerprinting Drug Screening System NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the " [...]
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
01/09/2026
PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and [...]
SCYNEXIS to Participate in Upcoming Investor Conferences
01/09/2026
JERSEY CITY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with [...]
CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab
01/09/2026
VANCOUVER, Washington, Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody [...]
DnaK Therapeutics & GATC Health Forge A Partnership To Evaluate, Accelerate & Prioritize Cancer Drug Candidates Using AI Platform
01/09/2026
The collaboration will utilize predictive artificial intelligence for identifying the most promising molecules from an expansive pipeline that will substantially accelerate proof of concept timelines and markedly reduce [...]
Celcuity To Participate in Upcoming Investor Conferences
01/09/2026
MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, [...]
Intelligent Bio Solutions Announces Private Placement of up to $15 Million to a Single Existing Institutional Investor Priced At-the-Market Under Nasdaq Rules
01/09/2026
$5 Million Upfront at Closing and $5 Million Tranche Warrant Callable by the Company Following FDA 510(k) Clearance of Intelligent Fingerprinting Drug Screening System NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- [...]
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
01/09/2026
Dr. Charlton brings over 15 years of rare disease and pediatric drug development experience including CMO and clinical development roles Appointment further strengthens clinical leadership and execution capabilities [...]
SAB BIO to Participate in Upcoming Investor Conferences
01/09/2026
MIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
Tris Pharma to Showcase ADHD Leadership and Commitment to Individualized Care at Fall 2026 Medical Conferences
01/09/2026
Company will exhibit at five major conferences this fall, engaging psychiatrists, pediatricians, child and adolescent psychiatrists, and the broader ADHD community Sponsored product theater presentations at US Psych [...]
Conexeu Sciences Sets September and October 2026 Conference Schedule
01/09/2026
RENO, Nev., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the “Company”), a preclinical-stage biotechnology company advancing an investigational tissue-restoration platform, is [...]
Spectral AI to Present at H.C. Wainwright 28th Annual Global Investment Conference
01/09/2026
Company to Highlight Growth Strategy and Readiness for 2026 Commercial Launch of FDA-Cleared DeepView® System for Burn Indication DALLAS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI [...]
Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026
01/09/2026
Abstracts highlight potential of Autonomix’s transvascular technology across pain management and nervous system mapping THE WOODLANDS, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“ [...]
Biomerica Reports Fiscal 2026 Year-End Financial Results
01/09/2026
Fiscal 2026 fourth quarter net sales increased approximately 17% compared to the fourth quarter of fiscal 2025 Full-year net loss improved by approximately 24% to approximately $3.8 million InFoods IBS update: 100% of [...]
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
01/09/2026
New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) ( [...]
BICEL™ SOFT TIP I/A terralution™. Gentle by Design. Sustainable by Nature*.
01/09/2026
Medicel AG expands its SOFT TIP I/A portfolio with the launch of BICEL™ SOFT TIP I/A terralution™ – bimanual sustainable I/A (irrigation / aspiration) for gentle tissue interaction – at the ESCRS Congress 2026 in London [...]
The Insides Company franchit une nouvelle étape vers le remboursement de son dispositif médical The Insides System® en France
01/09/2026
La Haute Autorité de Santé rend un avis favorable à l’inscription de The Insides System® sur la Liste des Produits et Prestations Remboursables (LPPR), franchissant une étape décisive vers une prise en charge pérenne [...]
Boehringer Ingelheim launches SCOVELLA® in Great Britain, the first approved therapy for insulin dysregulation in horses, a main cause of laminitis
01/09/2026
Ingelheim, Germany, and Bracknell, United Kingdom SCOVELLA® is the first therapy specifically developed and approved for the treatment of hyperinsulinemia in insulin-dysregulated horses and ponies 1 , targeting the key [...]
Transactions in connection with share buy-back program
01/09/2026
Company announcement no. 33 - 26 01 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]

Pages